In this episode, Dr. Morgentaler and Dr. Brandon discuss the controversial topic of testosterone therapy for men diagnosed with or treated for prostate cancer. 00:00: Introduction to Testosterone and Prostate Cancer - Dr. Morgentaler and Dr. Brandon set the stage by addressing common concerns about testosterone therapy for men with prostate cancer. 01:15: Impact of Androgen Deprivation Therapy - They discuss the effects of lowering testosterone on patients undergoing prostate cancer treatment and the long-term implications on quality of life. 03:22: Debunking Myths About Testosterone - The hosts confront the persistent fears surrounding testosterone and its perceived link to cancer recurrence. 07:40: Scientific Evidence and Case Studies - Highlighting studies and patient stories, they provide evidence that challenges outdated beliefs about testosterone therapy. 20:04: The Impact of Metastatic Disease on Life - They explore how metastatic prostate cancer affects physical and emotional well-being, emphasizing the need for balanced treatment approaches. 21:28: Understanding Biochemical Recurrence - The podcast explains the concept of biochemical recurrence, where cancer returns without visible signs, and its implications for therapy. 23:37: Testosterone Therapy After Prostate Cancer - They detail when and how testosterone therapy might be appropriate for patients post-treatment, backed by promising research data. 36:00: Concluding Thoughts and Future Directions - Wrapping up, they advocate for rethinking testosterone therapy guidelines and encourage further research to support evidence-based care. Resources: Watson, E., Chowdhury, S., & Williams, S. G. (2023). Testosterone therapy and prostate cancer: An update on current evidence and practice. Current Opinion in Urology, 33(6), 387–394. https://doi.org/10.1097/MOU.0000000000000989 Fralick, M., Kim, S. C., Schneeweiss, S., Glynn, R. J., Mittleman, M. A., Lee, H., & Patorno, E. (2023). Testosterone replacement therapy and risk of major adverse cardiovascular events. The New England Journal of Medicine, 388(10), 867–877. https://doi.org/10.1056/NEJMoa2215025 With Dr. Abraham Morgentaler and Dr. Marianne Brandon Listen to the podcast on all of your favorite platforms: Apple: https://podcasts.apple.com/ec/podcast/the-sex-doctors/id1761813985?l=en-GB Spotify: https://open.spotify.com/show/0apSFzquJXKoOGnmI6ndgT?si=e5a1e482c7ca46c7 Find us on: Instagram: https://www.instagram.com/thesexdoctors?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw== Facebook: https://www.facebook.com/thesexdoctors YouTube: https://www.youtube.com/@thesexdoctorspod TikTok: https://www.tiktok.com/@thesexdoctor LinkedIn (Dr. Abraham): https://www.linkedin.com/in/abraham-morgentaler-md-81628b6 LinkedIn (Dr. Marianne): https://www.linkedin.com/in/mariannebrandon-59224513 X (Dr. Abraham): https://x.com/DrMorgentaler X (Dr. Marianne): https://x.com/drbrandon #ProstateCancer #TestosteroneTherapy #MedicalMyths

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related